Fig. 2: Baseline and posttreatment anti-measles virus (MV) antibody levels. | Nature Communications

Fig. 2: Baseline and posttreatment anti-measles virus (MV) antibody levels.

From: Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial

Fig. 2

Error bars represent the standard error of the mean (SEM) A pre-treatment: n = 9 patients, mean =104.7 + /−13.0 SEM; A post treatment: n = 8 patients, mean=95.9 + /−14.6 SEM; B pre-treatment: n = 13 patients, mean=30.9 + /−10.4 SEM; B post treatment: n = 10 patients, mean=21.2 + /−10.2 SEM). Source data are provided as Source Data file.

Back to article page